Synapse - Michael Morris

Results (575)

Health-related quality of life and pain in a phase 3 study of [(177)Lu] Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Meeting Abstract

Fizazi, K.; Morris, M. J.; Shore, N. D.; Chi, K. N.; Crosby, M.; De Bono, J. S.; Herrmann, K.; Roubaud, G.; Nagarajah, J.; Fleming, M. T.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with (177)Lu-PSMA-617 versus change of ARPI in PSMAfore

Meeting Abstract

De Bono, J. S.; Morris, M. J.; Sartor, O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer

Meeting Abstract

Chen, R. C.; Mazza, G. L.; Fruth, B.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 ((225)Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Morris, M. J.; Wong, J. Y. C.; Nordquist, L.; Szmulewitz, R. Z.; Agarwal, N.; Attiyeh, E. F.; Max, S. I.; Divgi, C. R.; Patricia, D.; Cao, Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)

Meeting Abstract

Halabi, S.; Luo, B.; Guo, S. S.; Knutson, T.; Lyman, J.; Kobilka, A.; Beltran, H.; Antonarakis, E. S.; Rosenberg, J. E.; Galsky, M. D.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)

Meeting Abstract

Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient satisfaction with cancer care delivery through telemedicine at a comprehensive cancer center across three years during and after the COVID-19 pandemic

Meeting Abstract

Doshi, S. D.; Khadem Charvadeh, Y.; Seier, K.; Bange, E. M.; Daly, R. M.; Polubriaginof, F. C. G.; Buckley, M. T.; Kuperman, G.; Stetson, P. D.; Schrag, D.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient-reported experience with an immunotherapy telehealth platform

Meeting Abstract

Daly, R. M.; Bange, E. M.; Doshi, S. D.; Li, B. T.; Shah, N. J.; Aggen, D. H.; Kotecha, R. R.; Eng, J.; Ng, K. K.; Polubriaginof, F. C. G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Quantitative (68)Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following (177)Lu-PSMA-617 (VISION Trial)

Journal Article

Kuo, P. H.; Morris, M. J.; Hesterman, J.; Kendi, A. T.; Rahbar, K.; Wei, X. X.; Fang, B.; Adra, N.; Garje, R.; Michalski, J. M.; more...
Radiology (2024)

Fulltext@MSK | Save

Reply to J.A. Garcia et al

Correspondence

Halabi, S.; Guo, S.; Roy, A.; Rydzewska, L. E.; Godolphin, P.; Hussain, M.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save